Fresenius Medical Care stock at EUR 41.30, down 2.20%
Published on 11/09/2026 at 07:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Fresenius Medical Care operates dialysis-care and kidney-care businesses.
- US treatment trends remain important for the company's operating outlook.
- The recent focus is on a narrower 2026 operating-income outlook.
Fresenius Medical Care stock traded at EUR 41.30 on Lang & Schwarz at 07:43 CET on Monday, November 9, 2026, 2.20 percent below the Xetra close of Friday, November 6, at EUR 42.23.
The company operates in dialysis care and related kidney-care products, giving treatment volumes, reimbursement conditions and operating costs a direct bearing on earnings. US treatment trends remain a key business driver.
Outlook remains in focus
Recent company coverage has centered on a narrower 2026 operating-income outlook after third-quarter pressure. Transformation savings and share buybacks remain part of the investment discussion, while the outlook leaves execution and cost control as important near-term factors.
Investors can follow the real-time quote of Fresenius Medical Care stock during the European session.
The DAX will provide the broader market backdrop for German equities.
More news and analyses on Fresenius Medical Care stock are available on the dedicated topic page.
